Daridorexant: new hope for sleep disorders

A new study investigate about the dose-response of daridorexant, a new dual orexin receptor antagonist, on wake after sleep onset (WASO).

Elderly (≥65 years) participants (n = 58) with insomnia were randomly allocated to receive 5 treatments (5, 10, 25, and 50 mg daridorexant and placebo) during 5 treatment periods, each consisting of 2 treatment nights followed by a 5- to 12-day washout period. Main efficacy endpoints were the absolute change from baseline in WASO (primary) and latency to persistent sleep (LPS; secondary) to days 1 and 2 (mean of 2 treatment nights assessed by polysomnography) in each period. Safety and tolerability were also assessed.

Daridorexant was well tolerated. Dose-dependent improvements in WASO and LPS were statistically significant (dose range 10-50 mg) in elderly people with insomnia disorder.